Petricoin receives funding for project examining ovarian cancer detection with blood- and imaging-based biomarkers

Emanuel Petricoin, Co-Director, Center for Applied Proteomics and Molecular Medicine (CAPMM), received funding for a project examining ovarian cancer detection with blood- and imaging-based biomarkers.  

For this project, CAPMM researchers will receive tissue and sera samples from their university collaborator partners. The researchers will perform reverse phase protein array (RPPA) analysis and nanoparticle‐enabled biomarker capture and high-resolution mass spectrometry analysis on these specimens. The researchers will share and jointly analyze the results. 

"This exciting project aims to discover biomarkers in the blood to detect the earliest stages of ovarian cancer—looking at the premalignant lesions in the fallopian tube. The hope would be to combine blood and tissue based testing with imaging to detect ovarian cancer at the earliest premalignant stages," Petricoin said.  

Petricoin received $160,939 from the University of Arizona on a subaward from the U.S. Department of Health and Human Services for the first year of this five-year grant that began in January 2022. Total funding for the award will be $826,000.